Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
| Revenue (Most Recent Fiscal Year) | $3.50M |
| Net Income (Most Recent Fiscal Year) | $-63.73M |
| PE Ratio (Current Year Earnings Estimate) | 5.32 |
| PE Ratio (Trailing 12 Months) | 7.50 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.16 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 18188.50% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | 89.05% |
| Return on Assets (Trailing 12 Months) | 45.64% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.73 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.71 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.70 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 51.28M |
| Free Float | 47.74M |
| Market Capitalization | $353.82M |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |